Literature DB >> 25384261

Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up.

Mary C Zanarini1, Frances R Frankenburg, D Bradford Reich, Alayna L Harned, Garrett M Fitzmaurice.   

Abstract

The purpose of this study was to assess the classes and types of psychotropic medication reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up. Medication use was assessed at baseline using a semistructured interview of proven reliability and validity as well as its follow-up analog at 8 contiguous 2-year follow-up periods. A significantly higher percentage of borderline patients than axis II comparison subjects reported taking an antidepressant, an anxiolytic, an antipsychotic, and a mood stabilizer over time. They also reported more commonly taking 7 of the 10 more specific types of medication studied (ie, all but tricyclic antidepressants, monoamine oxidase inhibitor antidepressants, and atypical antipsychotics). The rates over time of taking antipsychotics and mood stabilizers were stable, whereas there was a significant decline in the rates of antidepressants and anxiolytics from baseline to 8-year follow-up (but not from 8- to 16-year follow-up) reported by those in both study groups. In terms of specific medications, rates of atypical antidepressants and anticonvulsants were the most stable. In contrast, nonbenzodiazepine anxiolytics declined the most steadily over time, whereas rates of atypical antipsychotics increased significantly over the 16 years of prospective follow-up. Taken together, the results of this study suggest that a substantial percentage of borderline patients continue to use the major classes of medication over time. They also suggest that the declining rates of use tend to stabilize less than a decade after index admission.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25384261      PMCID: PMC4276426          DOI: 10.1097/JCP.0000000000000232

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  15 in total

1.  Treatment histories of borderline inpatients.

Authors:  M C Zanarini; F R Frankenburg; G S Khera; J Bleichmar
Journal:  Compr Psychiatry       Date:  2001 Mar-Apr       Impact factor: 3.735

2.  Inter-rater and test-retest reliability of the Revised Diagnostic Interview for Borderlines.

Authors:  Mary C Zanarini; Frances R Frankenburg; A Anna Vujanovic
Journal:  J Pers Disord       Date:  2002-06

3.  Treatment utilization by patients with personality disorders.

Authors:  D S Bender; R T Dolan; A E Skodol; C A Sanislow; I R Dyck; T H McGlashan; M T Shea; M C Zanarini; J M Oldham; J G Gunderson
Journal:  Am J Psychiatry       Date:  2001-02       Impact factor: 18.112

4.  The diagnostic Interview for Personality Disorders: interrater and test-retest reliability.

Authors:  M C Zanarini; F R Frankenburg; D L Chauncey; J G Gunderson
Journal:  Compr Psychiatry       Date:  1987 Nov-Dec       Impact factor: 3.735

5.  Attainment and maintenance of reliability of axis I and II disorders over the course of a longitudinal study.

Authors:  M C Zanarini; F R Frankenburg
Journal:  Compr Psychiatry       Date:  2001 Sep-Oct       Impact factor: 3.735

6.  Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission.

Authors:  Mary C Zanarini; Frances R Frankenburg; John Hennen; D Bradford Reich; Kenneth R Silk
Journal:  Am J Psychiatry       Date:  2004-11       Impact factor: 18.112

7.  Is there a characteristic pattern to the treatment history of clinic outpatients with borderline personality?

Authors:  A E Skodol; P Buckley; E Charles
Journal:  J Nerv Ment Dis       Date:  1983-07       Impact factor: 2.254

8.  Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years.

Authors:  Mary C Zanarini; Frances R Frankenburg; John Hennen; Kenneth R Silk
Journal:  J Clin Psychiatry       Date:  2004-01       Impact factor: 4.384

9.  The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder.

Authors:  Mary C Zanarini; Frances R Frankenburg; John Hennen; Kenneth R Silk
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

10.  Pharmacotherapy of borderline outpatients.

Authors:  M C Zanarini; F R Frankenburg; J G Gunderson
Journal:  Compr Psychiatry       Date:  1988 Jul-Aug       Impact factor: 3.735

View more
  14 in total

Review 1.  The Lifetime Course of Borderline Personality Disorder.

Authors:  Robert S Biskin
Journal:  Can J Psychiatry       Date:  2015-07       Impact factor: 4.356

2.  Fluidity of the Subsyndromal Phenomenology of Borderline Personality Disorder Over 16 Years of Prospective Follow-Up.

Authors:  Mary C Zanarini; Frances R Frankenburg; D Bradford Reich; Garrett M Fitzmaurice
Journal:  Am J Psychiatry       Date:  2016-02-12       Impact factor: 18.112

3.  The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors.

Authors:  Rosa Shapiro-Thompson; Sarah K Fineberg
Journal:  Curr Treat Options Psychiatry       Date:  2022-03-04

4.  Co-use of medication and alcohol: The influence on subjective effects of intoxication and affect.

Authors:  Ashley C Helle; Andrea M Wycoff; Sarah A Griffin; Megan Fleming; Lindsey K Freeman; Tayler J Vebares; Elsa M Rodriguez; Maria F Zapata; Timothy J Trull
Journal:  Personal Disord       Date:  2021-01-18

5.  Levels of Depersonalization and Derealization Reported by Recovered and Non-recovered Borderline Patients Over 20 Years of Prospective Follow-up.

Authors:  Ravi Shah; Christina M Temes; Frances R Frankenburg; Garrett M Fitzmaurice; Mary C Zanarini
Journal:  J Trauma Dissociation       Date:  2020-01-30

6.  Bridging the Gap Between Remission and Recovery in BPD: Qualitative Versus Quantitative Perspectives.

Authors:  Paul H Soloff
Journal:  J Pers Disord       Date:  2019-02-20

Review 7.  What Works in the Treatment of Borderline Personality Disorder.

Authors:  Lois W Choi-Kain; Ellen F Finch; Sara R Masland; James A Jenkins; Brandon T Unruh
Journal:  Curr Behav Neurosci Rep       Date:  2017-02-03

8.  Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain.

Authors:  Juan C Pascual; Ana Martín-Blanco; Joaquim Soler
Journal:  CNS Drugs       Date:  2021-08-09       Impact factor: 5.749

9.  Mood Instability Is a Precursor of Relationship and Marital Difficulties: Results from Prospective Data from the British Health and Lifestyle Surveys.

Authors:  Rudy Cecil Bowen; Lisa Yue Dong; Evyn McMillan Peters; Marilyn Baetz; Lloyd Balbuena
Journal:  Front Psychiatry       Date:  2017-12-08       Impact factor: 4.157

10.  Psychotropic medication use in hospitalized patients with borderline personality disorder.

Authors:  Karen E Moeller; Amad Din; Macey Wolfe; Grant Holmes
Journal:  Ment Health Clin       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.